212 related articles for article (PubMed ID: 29757137)
1. Reversal of apixaban induced alterations in haemostasis by different coagulation factor concentrates in patients after hip or knee replacement surgery.
Schmidt K; Krüger K; Langer E; Schmutzler M; Johnen E; Wernecke KD; von Heymann C; Körber MK
Blood Transfus; 2019 Mar; 17(2):157-162. PubMed ID: 29757137
[TBL] [Abstract][Full Text] [Related]
2. Multimodal assessment of non-specific hemostatic agents for apixaban reversal.
Martin AC; Gouin-Thibault I; Siguret V; Mordohay A; Samama CM; Gaussem P; Le Bonniec B; Godier A
J Thromb Haemost; 2015 Mar; 13(3):426-36. PubMed ID: 25630710
[TBL] [Abstract][Full Text] [Related]
3. Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood.
Escolar G; Fernandez-Gallego V; Arellano-Rodrigo E; Roquer J; Reverter JC; Sanz VV; Molina P; Lopez-Vilchez I; Diaz-Ricart M; Galan AM
PLoS One; 2013; 8(11):e78696. PubMed ID: 24244342
[TBL] [Abstract][Full Text] [Related]
4. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.
Perzborn E; Heitmeier S; Laux V; Buchmüller A
Thromb Res; 2014 Apr; 133(4):671-81. PubMed ID: 24529498
[TBL] [Abstract][Full Text] [Related]
5. Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model.
Grottke O; van Ryn J; Spronk HM; Rossaint R
Crit Care; 2014 Feb; 18(1):R27. PubMed ID: 24499559
[TBL] [Abstract][Full Text] [Related]
6. In vitro reversal of supratherapeutic rivaroxaban levels with coagulation factor concentrates.
Körber MK; Langer E; Kaufner L; Sander M; Von Heymann C
Blood Transfus; 2016 Sep; 14(5):481-6. PubMed ID: 27177413
[TBL] [Abstract][Full Text] [Related]
7. Four-factor prothrombin complex concentrate reverses apixaban-associated bleeding in a rabbit model of acute hemorrhage.
Herzog E; Kaspereit F; Krege W; Mueller-Cohrs J; Doerr B; Niebl P; Dickneite G
J Thromb Haemost; 2015 Dec; 13(12):2220-6. PubMed ID: 26447393
[TBL] [Abstract][Full Text] [Related]
8. Ex vivo reversal of the anticoagulant effects of edoxaban.
Halim AB; Samama MM; Mendell J
Thromb Res; 2014 Oct; 134(4):909-13. PubMed ID: 25179520
[TBL] [Abstract][Full Text] [Related]
9. Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series.
Schultz NH; Lundblad R; Holme PA
J Med Case Rep; 2018 May; 12(1):138. PubMed ID: 29764497
[TBL] [Abstract][Full Text] [Related]
10. Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate.
Dinkelaar J; Patiwael S; Harenberg J; Leyte A; Brinkman HJ
Clin Chem Lab Med; 2014 Nov; 52(11):1615-23. PubMed ID: 24902009
[TBL] [Abstract][Full Text] [Related]
11. More efficient reversal of dabigatran inhibition of coagulation by activated prothrombin complex concentrate or recombinant factor VIIa than by four-factor prothrombin complex concentrate.
Lindahl TL; Wallstedt M; Gustafsson KM; Persson E; Hillarp A
Thromb Res; 2015 Mar; 135(3):544-7. PubMed ID: 25596769
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis.
Martin AC; Le Bonniec B; Fischer AM; Marchand-Leroux C; Gaussem P; Samama CM; Godier A
Int J Cardiol; 2013 Oct; 168(4):4228-33. PubMed ID: 23928345
[TBL] [Abstract][Full Text] [Related]
13. Influence of apixaban on commonly used coagulation assays: results from the Belgian national External Quality Assessment Scheme.
Van Blerk M; Bailleul E; Chatelain B; Demulder A; Devreese K; Douxfils J; Jacquemin M; Jochmans K; Mullier F; Wijns W; China B; Vernelen K; Soumali MR
Int J Lab Hematol; 2017 Aug; 39(4):402-408. PubMed ID: 28304137
[TBL] [Abstract][Full Text] [Related]
14. Measurement and reversal of prophylactic and therapeutic peak levels of rivaroxaban: an in vitro study.
Körber MK; Langer E; Ziemer S; Perzborn E; Gericke C; Heymann Cv
Clin Appl Thromb Hemost; 2014 Oct; 20(7):735-40. PubMed ID: 23832064
[TBL] [Abstract][Full Text] [Related]
15. Exploring the effect of factor Xa inhibitors on rotational thromboelastometry: a case series of bleeding patients.
Mahamad S; Chaudhry H; Nisenbaum R; McFarlan A; Rizoli S; Ackery A; Sholzberg M
J Thromb Thrombolysis; 2019 Feb; 47(2):272-279. PubMed ID: 30506352
[TBL] [Abstract][Full Text] [Related]
16. Measuring the activity of apixaban and rivaroxaban with rotational thrombelastometry.
Adelmann D; Wiegele M; Wohlgemuth RK; Koch S; Frantal S; Quehenberger P; Scharbert G; Kozek-Langenecker S; Schaden E
Thromb Res; 2014 Oct; 134(4):918-23. PubMed ID: 25179518
[TBL] [Abstract][Full Text] [Related]
17. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples.
Bonar R; Favaloro EJ; Mohammed S; Ahuja M; Pasalic L; Sioufi J; Marsden K
Pathology; 2016 Jan; 48(1):60-71. PubMed ID: 27020211
[TBL] [Abstract][Full Text] [Related]
18. Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study.
Song Y; Wang Z; Perlstein I; Wang J; LaCreta F; Frost RJA; Frost C
J Thromb Haemost; 2017 Nov; 15(11):2125-2137. PubMed ID: 28846831
[TBL] [Abstract][Full Text] [Related]
19. In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers.
Cheung YW; Barco S; Hutten BA; Meijers JC; Middeldorp S; Coppens M
J Thromb Haemost; 2015 Oct; 13(10):1799-805. PubMed ID: 26270625
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents.
Dale BJ; Ginsberg JS; Johnston M; Hirsh J; Weitz JI; Eikelboom JW
J Thromb Haemost; 2014 Nov; 12(11):1810-5. PubMed ID: 25196577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]